loading page

Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis
  • +1
  • Matteo Trimarchi,
  • Pietro Indelicato,
  • Alessandro Vinciguerra,
  • Mario Bussi
Matteo Trimarchi
Author Profile
Pietro Indelicato
San Raffaele Hospital
Author Profile
Alessandro Vinciguerra
San Raffaele Hospital
Author Profile
Mario Bussi
San Raffaele Hospital
Author Profile

Abstract

Chronic rhinosinusitis with nasal polyps is a type 2-mediated inflammatory disease associated with significant burden due to symptoms and high recurrence rate after surgery. Dupilumab, a monoclonal antibody against the interleukin-4 receptor subunit α, has demonstrated good clinical efficacy and acceptable safety in phase II and phase III trials.

Peer review status:ACCEPTED

18 Nov 2020Submitted to Clinical Case Reports
02 Dec 2020Submission Checks Completed
02 Dec 2020Assigned to Editor
08 Dec 2020Reviewer(s) Assigned
10 Dec 2020Review(s) Completed, Editorial Evaluation Pending
19 Dec 2020Editorial Decision: Revise Minor
22 Dec 20201st Revision Received
23 Dec 2020Submission Checks Completed
23 Dec 2020Assigned to Editor
23 Dec 2020Review(s) Completed, Editorial Evaluation Pending
28 Dec 2020Editorial Decision: Accept